Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zyvran Pharmaceuticals Inc. D/B/A Zyvran Pharmaceuticals D/B/A Zyvran Pharma currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to a distinct examiner, COPPINS, JANET L, who is also the busiest examiner for the portfolio. The prosecution activity is concentrated within a distinct art unit, indicating a highly focused examination path for the company's current filings.
Practitioners should note that the presence of 1 distinct examiner and art unit suggests a narrow technical scope for the pending portfolio. Because COPPINS, JANET L handles the active matter, the outcome of this specific case will define the current success rate for the portfolio in this technology area. The concentration in the assigned art unit simplifies the monitoring of examiner trends and procedural norms for the applicant. This streamlined structure allows for a direct engagement strategy with the assigned examiner, who manages the entirety of the company's pending workload. The alignment of these figures reflects a consolidated approach to intellectual property management at this stage. By focusing on the specific preferences and historical data of the assigned official, the applicant can optimize their response strategy for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18238229 | TREATMENT COMPOSITION FOR MILD COGNITIVE IMPAIRMENT AND DEMENTIA | COPPINS, JANET L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18238229 | TREATMENT COMPOSITION FOR MILD COGNITIVE IMPAIRMENT AND DEMENTIA | COPPINS, JANET L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18238229 | TREATMENT COMPOSITION FOR MILD COGNITIVE IMPAIRMENT AND DEMENTIA | COPPINS, JANET L | 1628 | §102§103§112 | Non-Final OA | — | Pending | Aug 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZyvran Pharmaceuticals Inc. D/B/A Zyvran Pharmaceuticals D/B/A Zyvran Pharma has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Janet L Coppins has the most, with 1 of Zyvran Pharmaceuticals Inc. D/B/A Zyvran Pharmaceuticals D/B/A Zyvran Pharma's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
